Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will attend the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. This forum provides a platform for experts in nasal drug development to discuss innovations and regulatory considerations, making it a strategic venue for Silo to showcase its progress with SPC-15, its lead candidate for post-traumatic stress disorder (PTSD).
The company's participation comes on the heels of encouraging preclinical data demonstrating that the SPC-15 formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent with long-term stability findings, indicating the product's robustness. These results are pivotal as Silo advances SPC-15's novel nose-to-brain delivery approach, which aims to target the central nervous system directly, potentially improving efficacy and reducing systemic side effects compared to traditional delivery methods.
Eric Weisblum, CEO of Silo Pharma, emphasized the importance of the forum in fostering collaboration with industry leaders. "The IPAC-RS Nasal Innovation Forum offers an ideal opportunity to engage with experts in nasal drug development as we continue to advance SPC-15's novel nose-to-brain approach to targeted drug delivery for the treatment of PTSD," he stated in the press release. This engagement is part of Silo's broader strategy to leverage partnerships and scientific exchange to accelerate its pipeline.
Silo Pharma is a diversified biopharmaceutical and cryptocurrency treasury company with a therapeutic focus on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company conducts research in collaboration with leading universities and laboratories, as highlighted on its website at silopharma.com.
The announcement is significant as it highlights Silo's commitment to addressing the substantial unmet need in PTSD treatment. PTSD affects millions worldwide, and current therapies often have limited efficacy or are associated with significant side effects. SPC-15's intranasal delivery intends to facilitate rapid absorption and targeted action, potentially offering a more convenient and effective treatment option. The stability data presented suggest that SPC-15 is nearing a stage where regulatory discussions and further clinical development can proceed with confidence.
Furthermore, Silo's participation in the forum aligns with its broader mission to innovate in drug delivery systems. The company's dedication to advancing SPC-15 is underscored by its ongoing research and collaborations, which may pave the way for other CNS-targeted therapies in its pipeline. As the company continues to meet these milestones, stakeholders will be watching closely for updates on SPC-15's development trajectory.
For more information on Silo Pharma and its latest updates, visit the company's newsroom at https://ibn.fm/SILO.
